Review



monoclonal antibody targeting il 17a  (Bio X Cell)


Bioz Verified Symbol Bio X Cell is a verified supplier
Bioz Manufacturer Symbol Bio X Cell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Bio X Cell monoclonal antibody targeting il 17a
    ( A ) Immunofluorescence staining and quantification of <t>IL-17a</t> + cells in skin tissue from rats treated with DHT p.o. + FeCl 3 s.c. or vehicle p.o. + H 2 O s.c. (representative images; n = 5 animals per group). Scale bar: 50 μm. ( B ) Schematic of the IL-17a mAb experimental timeline. ( C ) Gross images of dorsal skin lesions. Black arrowheads show visible regions of calcification. ( D ) Representative von Kossa–stained images of rat dermal tissue highlighting calcified regions (arrowheads). Quantification of calcified percentage in the IL-17a mAb–treated group ( n = 12) compared with IgG control ( n = 8). ( E ) Top 5 KEGG pathways enriched in DEGs between IgG-treated ( n = 3 animals) and IL-17a mAb–treated rats following DHT p.o. + FeCl 3 s.c. ( n = 3 animals). ( F ) Enriched genes in IL-17 signaling pathway. Data are represented as mean ± SEM. *** P < 0.001, 2-tailed Student’s t test.
    Monoclonal Antibody Targeting Il 17a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 176 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+targeting+il+17a/InVivoPlus+anti-mouse+IL-17A/pmc12483568-149-17-23
    Average 95 stars, based on 176 article reviews
    monoclonal antibody targeting il 17a - by Bioz Stars, 2026-10
    95/100 stars

    Images

    1) Product Images from "Pharmacological targeting of the IL-17/neutrophil axis attenuates calcific deposits in rat models of calciphylaxis"

    Article Title: Pharmacological targeting of the IL-17/neutrophil axis attenuates calcific deposits in rat models of calciphylaxis

    Journal: The Journal of Clinical Investigation

    doi: 10.1172/JCI190369

    ( A ) Immunofluorescence staining and quantification of IL-17a + cells in skin tissue from rats treated with DHT p.o. + FeCl 3 s.c. or vehicle p.o. + H 2 O s.c. (representative images; n = 5 animals per group). Scale bar: 50 μm. ( B ) Schematic of the IL-17a mAb experimental timeline. ( C ) Gross images of dorsal skin lesions. Black arrowheads show visible regions of calcification. ( D ) Representative von Kossa–stained images of rat dermal tissue highlighting calcified regions (arrowheads). Quantification of calcified percentage in the IL-17a mAb–treated group ( n = 12) compared with IgG control ( n = 8). ( E ) Top 5 KEGG pathways enriched in DEGs between IgG-treated ( n = 3 animals) and IL-17a mAb–treated rats following DHT p.o. + FeCl 3 s.c. ( n = 3 animals). ( F ) Enriched genes in IL-17 signaling pathway. Data are represented as mean ± SEM. *** P < 0.001, 2-tailed Student’s t test.
    Figure Legend Snippet: ( A ) Immunofluorescence staining and quantification of IL-17a + cells in skin tissue from rats treated with DHT p.o. + FeCl 3 s.c. or vehicle p.o. + H 2 O s.c. (representative images; n = 5 animals per group). Scale bar: 50 μm. ( B ) Schematic of the IL-17a mAb experimental timeline. ( C ) Gross images of dorsal skin lesions. Black arrowheads show visible regions of calcification. ( D ) Representative von Kossa–stained images of rat dermal tissue highlighting calcified regions (arrowheads). Quantification of calcified percentage in the IL-17a mAb–treated group ( n = 12) compared with IgG control ( n = 8). ( E ) Top 5 KEGG pathways enriched in DEGs between IgG-treated ( n = 3 animals) and IL-17a mAb–treated rats following DHT p.o. + FeCl 3 s.c. ( n = 3 animals). ( F ) Enriched genes in IL-17 signaling pathway. Data are represented as mean ± SEM. *** P < 0.001, 2-tailed Student’s t test.

    Techniques Used: Immunofluorescence, Staining, Control

    Related Articles

    Injection:

    Article Title: Pharmacological targeting of the IL-17/neutrophil axis attenuates calcific deposits in rat models of calciphylaxis
    Article Snippet: .. To determine the specific role of IL-17 in mediating calcific deposits, we injected the animals with a monoclonal antibody targeting IL-17a (IL-17a mAb, Bio X Cell, BP0173). ..



    Similar Products

    monoclonal antibody targeting il 17a  (Bio X Cell)
    95
    Bio X Cell monoclonal antibody targeting il 17a
    ( A ) Immunofluorescence staining and quantification of <t>IL-17a</t> + cells in skin tissue from rats treated with DHT p.o. + FeCl 3 s.c. or vehicle p.o. + H 2 O s.c. (representative images; n = 5 animals per group). Scale bar: 50 μm. ( B ) Schematic of the IL-17a mAb experimental timeline. ( C ) Gross images of dorsal skin lesions. Black arrowheads show visible regions of calcification. ( D ) Representative von Kossa–stained images of rat dermal tissue highlighting calcified regions (arrowheads). Quantification of calcified percentage in the IL-17a mAb–treated group ( n = 12) compared with IgG control ( n = 8). ( E ) Top 5 KEGG pathways enriched in DEGs between IgG-treated ( n = 3 animals) and IL-17a mAb–treated rats following DHT p.o. + FeCl 3 s.c. ( n = 3 animals). ( F ) Enriched genes in IL-17 signaling pathway. Data are represented as mean ± SEM. *** P < 0.001, 2-tailed Student’s t test.
    Monoclonal Antibody Targeting Il 17a, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+targeting+il+17a/InVivoPlus+anti-mouse+IL-17A/pmc12483568-149-17-23
    Average 95 stars, based on 1 article reviews
    monoclonal antibody targeting il 17a - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    humanized igg1κ monoclonal antibody targeting il-17a cjm112  (Novartis)
    90
    Novartis humanized igg1κ monoclonal antibody targeting il-17a cjm112
    ( A ) Immunofluorescence staining and quantification of <t>IL-17a</t> + cells in skin tissue from rats treated with DHT p.o. + FeCl 3 s.c. or vehicle p.o. + H 2 O s.c. (representative images; n = 5 animals per group). Scale bar: 50 μm. ( B ) Schematic of the IL-17a mAb experimental timeline. ( C ) Gross images of dorsal skin lesions. Black arrowheads show visible regions of calcification. ( D ) Representative von Kossa–stained images of rat dermal tissue highlighting calcified regions (arrowheads). Quantification of calcified percentage in the IL-17a mAb–treated group ( n = 12) compared with IgG control ( n = 8). ( E ) Top 5 KEGG pathways enriched in DEGs between IgG-treated ( n = 3 animals) and IL-17a mAb–treated rats following DHT p.o. + FeCl 3 s.c. ( n = 3 animals). ( F ) Enriched genes in IL-17 signaling pathway. Data are represented as mean ± SEM. *** P < 0.001, 2-tailed Student’s t test.
    Humanized Igg1κ Monoclonal Antibody Targeting Il 17a Cjm112, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+targeting+il+17a/secukinumab+cosentyx/pm39251215-48-0-12
    Average 90 stars, based on 1 article reviews
    humanized igg1κ monoclonal antibody targeting il-17a cjm112 - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    secukinumab is a fully human monoclonal antibody that specifically targets and neutralizes il-17a  (Novartis)
    90
    Novartis secukinumab is a fully human monoclonal antibody that specifically targets and neutralizes il-17a
    ( A ) Immunofluorescence staining and quantification of <t>IL-17a</t> + cells in skin tissue from rats treated with DHT p.o. + FeCl 3 s.c. or vehicle p.o. + H 2 O s.c. (representative images; n = 5 animals per group). Scale bar: 50 μm. ( B ) Schematic of the IL-17a mAb experimental timeline. ( C ) Gross images of dorsal skin lesions. Black arrowheads show visible regions of calcification. ( D ) Representative von Kossa–stained images of rat dermal tissue highlighting calcified regions (arrowheads). Quantification of calcified percentage in the IL-17a mAb–treated group ( n = 12) compared with IgG control ( n = 8). ( E ) Top 5 KEGG pathways enriched in DEGs between IgG-treated ( n = 3 animals) and IL-17a mAb–treated rats following DHT p.o. + FeCl 3 s.c. ( n = 3 animals). ( F ) Enriched genes in IL-17 signaling pathway. Data are represented as mean ± SEM. *** P < 0.001, 2-tailed Student’s t test.
    Secukinumab Is A Fully Human Monoclonal Antibody That Specifically Targets And Neutralizes Il 17a, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+targeting+il+17a/secukinumab+cosentyx/pmc11368109-110-37-24
    Average 90 stars, based on 1 article reviews
    secukinumab is a fully human monoclonal antibody that specifically targets and neutralizes il-17a - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    fully human monoclonal antihuman antibody of the igg1/kappa isotype that selectively targets il-17a  (Novartis)
    90
    Novartis fully human monoclonal antihuman antibody of the igg1/kappa isotype that selectively targets il-17a
    ( A ) Immunofluorescence staining and quantification of <t>IL-17a</t> + cells in skin tissue from rats treated with DHT p.o. + FeCl 3 s.c. or vehicle p.o. + H 2 O s.c. (representative images; n = 5 animals per group). Scale bar: 50 μm. ( B ) Schematic of the IL-17a mAb experimental timeline. ( C ) Gross images of dorsal skin lesions. Black arrowheads show visible regions of calcification. ( D ) Representative von Kossa–stained images of rat dermal tissue highlighting calcified regions (arrowheads). Quantification of calcified percentage in the IL-17a mAb–treated group ( n = 12) compared with IgG control ( n = 8). ( E ) Top 5 KEGG pathways enriched in DEGs between IgG-treated ( n = 3 animals) and IL-17a mAb–treated rats following DHT p.o. + FeCl 3 s.c. ( n = 3 animals). ( F ) Enriched genes in IL-17 signaling pathway. Data are represented as mean ± SEM. *** P < 0.001, 2-tailed Student’s t test.
    Fully Human Monoclonal Antihuman Antibody Of The Igg1/Kappa Isotype That Selectively Targets Il 17a, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+targeting+il+17a/gwn323+antibody/pm32514862-44-20-27
    Average 90 stars, based on 1 article reviews
    fully human monoclonal antihuman antibody of the igg1/kappa isotype that selectively targets il-17a - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    monoclonal antibodies targeting il-17a secukinumab  (Novartis)
    90
    Novartis monoclonal antibodies targeting il-17a secukinumab
    ( A ) Immunofluorescence staining and quantification of <t>IL-17a</t> + cells in skin tissue from rats treated with DHT p.o. + FeCl 3 s.c. or vehicle p.o. + H 2 O s.c. (representative images; n = 5 animals per group). Scale bar: 50 μm. ( B ) Schematic of the IL-17a mAb experimental timeline. ( C ) Gross images of dorsal skin lesions. Black arrowheads show visible regions of calcification. ( D ) Representative von Kossa–stained images of rat dermal tissue highlighting calcified regions (arrowheads). Quantification of calcified percentage in the IL-17a mAb–treated group ( n = 12) compared with IgG control ( n = 8). ( E ) Top 5 KEGG pathways enriched in DEGs between IgG-treated ( n = 3 animals) and IL-17a mAb–treated rats following DHT p.o. + FeCl 3 s.c. ( n = 3 animals). ( F ) Enriched genes in IL-17 signaling pathway. Data are represented as mean ± SEM. *** P < 0.001, 2-tailed Student’s t test.
    Monoclonal Antibodies Targeting Il 17a Secukinumab, supplied by Novartis, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/monoclonal+antibody+targeting+il+17a/secukinumab+cosentyx/pm26781775-12-9-11
    Average 90 stars, based on 1 article reviews
    monoclonal antibodies targeting il-17a secukinumab - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Immunofluorescence staining and quantification of IL-17a + cells in skin tissue from rats treated with DHT p.o. + FeCl 3 s.c. or vehicle p.o. + H 2 O s.c. (representative images; n = 5 animals per group). Scale bar: 50 μm. ( B ) Schematic of the IL-17a mAb experimental timeline. ( C ) Gross images of dorsal skin lesions. Black arrowheads show visible regions of calcification. ( D ) Representative von Kossa–stained images of rat dermal tissue highlighting calcified regions (arrowheads). Quantification of calcified percentage in the IL-17a mAb–treated group ( n = 12) compared with IgG control ( n = 8). ( E ) Top 5 KEGG pathways enriched in DEGs between IgG-treated ( n = 3 animals) and IL-17a mAb–treated rats following DHT p.o. + FeCl 3 s.c. ( n = 3 animals). ( F ) Enriched genes in IL-17 signaling pathway. Data are represented as mean ± SEM. *** P < 0.001, 2-tailed Student’s t test.

    Journal: The Journal of Clinical Investigation

    Article Title: Pharmacological targeting of the IL-17/neutrophil axis attenuates calcific deposits in rat models of calciphylaxis

    doi: 10.1172/JCI190369

    Figure Lengend Snippet: ( A ) Immunofluorescence staining and quantification of IL-17a + cells in skin tissue from rats treated with DHT p.o. + FeCl 3 s.c. or vehicle p.o. + H 2 O s.c. (representative images; n = 5 animals per group). Scale bar: 50 μm. ( B ) Schematic of the IL-17a mAb experimental timeline. ( C ) Gross images of dorsal skin lesions. Black arrowheads show visible regions of calcification. ( D ) Representative von Kossa–stained images of rat dermal tissue highlighting calcified regions (arrowheads). Quantification of calcified percentage in the IL-17a mAb–treated group ( n = 12) compared with IgG control ( n = 8). ( E ) Top 5 KEGG pathways enriched in DEGs between IgG-treated ( n = 3 animals) and IL-17a mAb–treated rats following DHT p.o. + FeCl 3 s.c. ( n = 3 animals). ( F ) Enriched genes in IL-17 signaling pathway. Data are represented as mean ± SEM. *** P < 0.001, 2-tailed Student’s t test.

    Article Snippet: To determine the specific role of IL-17 in mediating calcific deposits, we injected the animals with a monoclonal antibody targeting IL-17a (IL-17a mAb, Bio X Cell, BP0173).

    Techniques: Immunofluorescence, Staining, Control